Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Adaptive licensing: A new approach for authorizing medicines

Stephen O’Brien • 12 Jun 2015
EHA 2015
General

At the 20th Congress of the European Hematology Association (EHA), Stephen O’Brien, BSc (Hons), PhD, MBChB, FRCP, FRCPath, of the University of Newcastle, Newcastle upon Tyne, UK, explains the process of adaptive licensing of new medicines, which aims to improve timely access for patients to new medicines.

More from Stephen O’Brien

Engaging patients in clinical research
2:03
Engaging patients in clinical research
Stephen O’Brien • 12 Jun 2015
Outlook for the management of chronic myeloid leukemia
1:38
Outlook for the management of chronic myeloid leukemia
Stephen O’Brien • 12 Jun 2015
SPIRIT2 trial on dasatinib for AML - safety and side effect management
2:29
SPIRIT2 trial on dasatinib for AML - safety and side effect management
Stephen O’Brien • 18 Apr 2016

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI in clinical decision-making
2:25
Addressing the risk of over-reliance on AI in clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026
The content of VJHemOnc is intended for healthcare professionals